A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
The MarketWatch News Department was not involved in the creation of this content. Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized ...
SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program ...
Treatment strategies for HHT are limited to symptom management as there are currently no approved therapeutics for the disease. “DIAG723 represents a powerful new approach to treating HHT, supported ...
In a review of published research papers, investigators from the Johns Hopkins Medicine Hereditary Hemorrhagic Telangiectasia (HHT) Center have identified a substantial lack of racial and ethnic data ...
In a review of published research papers, investigators from the Johns Hopkins Medicine Hereditary Hemorrhagic Telangiectasia (HHT) Center have identified a substantial lack of racial and ethnic data ...
The MarketWatch News Department was not involved in the creation of this content. -- Proceeds will support the advancement of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback